Xbrane Biopharma informs about ongoing negotiations concerning out-licensing of Spherotide to China
In accordance with what has previously been communicated in press releases, interim reports and presentations, Xbrane is in discussions and negotiations with potential partners regarding out-licensing of Spherotide and Xlucane. One of these negotiations concerns out-licensing of the rights to sell and market Spherotide in China to a large Chinese company.
Final negotiation for the agreement took place during the Chinese partner's visit in Sweden and in Italy in December. The Company has earlier announced that the final agreement was expected to be entered during 2017 but can now inform that the entering of the agreement is expected to take place during the first quarter of 2018.
For further information, please contact:
Martin Åmark, CEO, Xbrane Biopharma AB
M: +46 (0) 763-093 777
Susanna Helgesen, CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified advisor. For more information see www.xbrane.com.
This information is information that Xbrane Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU) no. 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 23.45, 21 December 2017.